Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 8.22
-0.18 (-2.14%)
At close: Aug 14, 2026
Abera Bioscience AB Market Cap
Abera Bioscience AB has a market cap or net worth of 168.5 million as of August 14, 2026. Its market cap has increased by 48.32% in one year.
Market Cap
168.50M
Enterprise Value
142.46M
Revenue
11.83M
Ranking
n/a
PE Ratio
n/a
Stock Price
8.22
ChartMarket Cap Chart
Since February 24, 2021, Abera Bioscience AB's market cap has increased from 115.59M to 168.50M, an increase of 45.78%. That is a compound annual growth rate of 7.13%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 14, 2026 | 168.50M | 34.33% |
| Dec 30, 2025 | 125.44M | 81.17% |
| Dec 30, 2024 | 69.24M | -7.23% |
| Dec 29, 2023 | 74.63M | 20.46% |
| Dec 30, 2022 | 61.96M | -64.21% |
| Dec 30, 2021 | 173.12M | 49.77% |
| Feb 24, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Alzinova AB | 203.05M |
| Xbrane Biopharma AB | 200.70M |
| Elicera Therapeutics AB | 196.54M |
| Initiator Pharma | 170.45M |
| Xintela AB | 160.20M |
| Diamyd Medical AB | 158.39M |
| Nanologica AB | 153.54M |
| Biovica International AB | 151.79M |